@Article{crph1010,
AUTHOR = {Gorani, Manas},
TITLE = {Revolutionizing Active Pharmaceutical Ingredients: From Concept to Compliance},
JOURNAL = {Current Research in Public Health},
VOLUME = {3},
YEAR = {2024},
NUMBER = {1},
PAGES = {27-32},
URL = {https://www.scipublications.com/journal/index.php/UJPP/article/view/1010},
ISSN = {2831-5162},
DOI = {10.31586/ujpp.2024.1010},
ABSTRACT = {Active Pharmaceutical Ingredients (APIs) serve as the cornerstone of pharmaceutical development, driving therapeutic efficacy and safety in drug formulations. This article provides a comprehensive overview of the lifecycle of APIs, starting from their discovery and development, through to manufacturing processes and regulatory oversight. The development of APIs begins with intensive research and discovery efforts, where medicinal chemists and pharmacologists identify and optimize potential compounds through computational modelling, high-throughput screening, and structure-activity relationship studies. Promising candidates undergo rigorous preclinical testing to assess pharmacological properties, safety profiles, and potential adverse effects in animal models. Upon successful preclinical outcomes, APIs progress to clinical trials, involving phases of testing in human subjects to evaluate efficacy, dosage regimens, and safety profiles under controlled conditions. Clinical trial data are meticulously analyzed to support regulatory submissions, demonstrating the API's therapeutic benefits and safety for eventual patient use. Manufacturing APIs involves complex chemical synthesis or biotechnological methods, ensuring precise control over reaction conditions, purity, and yield. The scale-up from laboratory synthesis to industrial production demands adherence to Good Manufacturing Practices (GMP), where stringent quality control measures verify consistency, potency, and stability throughout production batches. Regulatory oversight by authorities such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe ensures that APIs meet stringent standards of safety, efficacy, and quality before market approval. Manufacturers must submit comprehensive Chemistry, Manufacturing, and Controls (CMC) data, detailing manufacturing processes, analytical methods, and stability studies to support regulatory filings.},
}

%0 Journal Article
%A Gorani, Manas
%D 2024
%J Current Research in Public Health

%@ 2831-5162
%V 3
%N 1
%P 27-32

%T Revolutionizing Active Pharmaceutical Ingredients: From Concept to Compliance
%M doi:10.31586/ujpp.2024.1010
%U https://www.scipublications.com/journal/index.php/UJPP/article/view/1010

TY  - JOUR
AU  - Gorani, Manas
TI  - Revolutionizing Active Pharmaceutical Ingredients: From Concept to Compliance
T2  - Current Research in Public Health
PY  - 2024
VL  - 3
IS  - 1
SN  - 2831-5162
SP  - 27
EP  - 32
UR  - https://www.scipublications.com/journal/index.php/UJPP/article/view/1010
AB  - Active Pharmaceutical Ingredients (APIs) serve as the cornerstone of pharmaceutical development, driving therapeutic efficacy and safety in drug formulations. This article provides a comprehensive overview of the lifecycle of APIs, starting from their discovery and development, through to manufacturing processes and regulatory oversight. The development of APIs begins with intensive research and discovery efforts, where medicinal chemists and pharmacologists identify and optimize potential compounds through computational modelling, high-throughput screening, and structure-activity relationship studies. Promising candidates undergo rigorous preclinical testing to assess pharmacological properties, safety profiles, and potential adverse effects in animal models. Upon successful preclinical outcomes, APIs progress to clinical trials, involving phases of testing in human subjects to evaluate efficacy, dosage regimens, and safety profiles under controlled conditions. Clinical trial data are meticulously analyzed to support regulatory submissions, demonstrating the API's therapeutic benefits and safety for eventual patient use. Manufacturing APIs involves complex chemical synthesis or biotechnological methods, ensuring precise control over reaction conditions, purity, and yield. The scale-up from laboratory synthesis to industrial production demands adherence to Good Manufacturing Practices (GMP), where stringent quality control measures verify consistency, potency, and stability throughout production batches. Regulatory oversight by authorities such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe ensures that APIs meet stringent standards of safety, efficacy, and quality before market approval. Manufacturers must submit comprehensive Chemistry, Manufacturing, and Controls (CMC) data, detailing manufacturing processes, analytical methods, and stability studies to support regulatory filings.
DO  - Revolutionizing Active Pharmaceutical Ingredients: From Concept to Compliance
TI  - 10.31586/ujpp.2024.1010
ER  -